It seems a little strange that a company with a cancer drug that's completed enrollment in a P3 trial and has started two other P3 trials, and with another drug that's shown promise in P1 and P2 trials and is also in or about to begin other randomized P2 trials, has a market cap of under $180 million. Is it because it's under the radar, or because people think that since the drugs are antisense the trials will fail, or because they think even if SYNERGY succeeds 011 will struggle when competing with newer drugs that don't need to be combined with chemo? (I think Jevtana's success and other evidence shows that chemo isn't going away.)
Hard to say, but now we're up against the "fiscal cliff" that's likely to rattle the markets until a "grand bargain" (that will probably involve unnecessary cuts to Social Security and Medicare) is struck. I don't know what it will take to wake up this stock. Maybe just the approach of the release of SYNERGY data -- estimated for around the end of 2013 -- will do it. Or maybe there will be a positive development out of left field, such as an announcement that Teva is funding a new trial or that J&J will help fund the 427/Zytiga trial, but that seems unlikely.
I hate this new Yahoo format, which seems to be discouraging people from posting. Obviously Marissa Mayer has never posted on a Yahoo board.
I am as surprised as you however this cloud has a silver lining I have been buying the stock every day at these prices. The shorts in this stock have been covering pretty aggresively and they have been right with this name.